London, January 12, 2026, 08:41 GMT — Regular session
- GSK shares held firm in early London trading as investors focused on healthcare conferences.
- On Tuesday morning, GSK is scheduled to appear at a JPMorgan conference, joining several other major drugmakers.
- Traders are eyeing GSK’s full-year results scheduled for early February.
Shares of GSK plc edged down 0.03% to 1,885.5 pence early Monday in London, after fluctuating between 1,870.5 and 1,885.5 pence during the session.
The annual J.P. Morgan Healthcare Conference takes place January 12–15 in San Francisco. According to the agenda, GSK is scheduled for a 7:30 a.m. Pacific slot on Tuesday, followed by AstraZeneca later that morning.
The San Francisco meetings this week often set the initial tone for big drugmakers each year — focusing on pipelines, pricing, and occasionally deals. Investors are on the lookout for any news that could alter expectations ahead of upcoming quarterly results.
In the U.S., GSK’s American depositary receipts (ADRs)—which represent shares listed stateside—closed the session up 0.3%, at $50.39.
Dealmaking continues to shape the landscape. According to the Financial Times, drugs generating roughly $180 billion in annual revenue will go off patent in 2027 and 2028, citing data from Evaluate Pharma. JPMorgan healthcare banker Jeremy Meilman told the paper, “The need to take big swings becomes more pressing.” 1
Closer to home, British newspaper The Times reported renewed speculation about a possible merger between GSK and AstraZeneca. The paper, however, called the idea unlikely and noted that both companies declined to comment.
GSK grabbed investors’ focus last week after announcing its experimental chronic hepatitis B treatment hit the primary endpoint in two trials and that it intends to file for regulatory approval. The company didn’t reveal how many patients achieved a “functional cure” — defined as a lasting drop in critical virus markers without continued therapy. Analysts said they’ll need the full dataset to properly assess the drug’s market potential.
It also highlighted a vaccine update during the week. GSK announced that the European Commission has approved a prefilled syringe version of its shingles vaccine, Shingrix. Chief Scientific Officer Tony Wood said this new format aims to simplify administration for healthcare professionals.
Conference week doesn’t always deliver concrete numbers. Brief remarks can swing expectations either way. Investors will probably hold off until the next batch of detailed data appears and reveals its impact on guidance.
GSK is set to release its full-year and fourth-quarter results on February 4. 2
